12135 studies found for:    "Vascular Diseases"
Show Display Options
Rank Status Study
21 Unknown  Safety Study of Using Stem Cells to Stimulate Development of New Blood Vessels in Peripheral Vascular Disease
Condition: Peripheral Vascular Diseases
Intervention: Drug: adult stem cells
22 Active, not recruiting Systematic Assessment of Vascular Risk
Condition: Peripheral Vascular Disease
Intervention:
23 Unknown  Noninvasive Predictors of Transplant Vasculopathy
Condition: Cardiac Allograft Vasculopathy
Intervention:
24 Terminated The ABSORB BTK (Below The Knee) Clinical Investigation
Conditions: Atherosclerosis;   Peripheral Artery Disease;   Peripheral Vascular Disease;   PAD;   Claudication;   Critical Limb Ischemia;   Lower Limb Disease;   Peripheral Arterial Occlusive Disease;   PAOD;   PVD
Intervention: Device: Everolimus Eluting BVS
25 Unknown  Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Intervention: Drug: Intravitreal Bevacizumab
26 Completed Effect of VascuActive Device on Foot Perfusion, Hemodynamics and Exercise Capacity in Patients With PVD & Limb Ischemia
Condition: Peripheral Vascular Diseases
Intervention: Device: VascuActive
27 Unknown  Noninvasive Evaluation of Cardiac Allograft Vasculopathy
Condition: Cardiac Allograft Vasculopathy
Intervention:
28 Active, not recruiting ESPRIT I: A Clinical Evaluation of the Abbott Vascular ESPRIT BVS (Bioresorbable Vascular Scaffold) System
Conditions: Atherosclerosis;   Peripheral Vascular Disease;   Claudication
Intervention: Device: ESPRIT BVS
29 Completed
Has Results
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Intervention: Drug: ranibizumab 0.5 or 0.3 mg/0.05 cc
30 Unknown  Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Intervention: Drug: ranibizumab 2.0mg
31 Active, not recruiting Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Intervention: Drug: ranibizumab 0.5 or 2.0 mg/0.05 cc
32 Active, not recruiting Optical Coherence Tomography (OCT) to Evaluate Cardiac Allograft Vasculopathy (CAV) in Patient's Post Heart Transplant
Condition: Cardiac Allograft Vasculopathy
Intervention:
33 Completed Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs
Condition: Polypoidal Choroidal Vasculopathy
Intervention:
34 Suspended Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
Condition: Cardiac Allograft Vasculopathy
Intervention: Drug: Sirolimus
35 Recruiting Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy
Condition: Cardiac Allograft Vasculopathy
Intervention: Device: Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)
36 Completed Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
Conditions: PCV;   Polypoidal Choroidal Vasculopathy
Interventions: Drug: high-dose ranibizumab;   Drug: ranibizumab
37 Active, not recruiting Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
Conditions: Peripheral Artery Disease;   Peripheral Vascular Disease;   Vascular Disease;   Cardiovascular Diseases;   PAD
Intervention: Device: FlexStent® Femoropopliteal Self Expanding Stent System
38 Completed Prevention of Recurrent Venous Thromboembolism (PREVENT)
Conditions: Cardiovascular Diseases;   Heart Diseases;   Peripheral Vascular Diseases;   Thromboembolism;   Vascular Diseases;   Venous Thromboembolism
Intervention: Drug: warfarin
39 Completed Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)
Condition: Polypoidal Choroidal Vasculopathy
Interventions: Drug: fosbretabulin;   Drug: Saline
40 Completed
Has Results
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
Condition: Polypoidal Choroidal Vasculopathy
Interventions: Drug: Verteporfin Photodynamic Therapy;   Drug: Ranibizumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years